The efficacy and safety of the Gefapixant in patients with interstitial lung disease

JRCT ID: jRCT1031220275

Registered date:17/08/2022

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: interstitial lung disease
• Date of first enrollment: 17/08/2022
• Target sample size: 30
• Study type: Observational

Outcome(s)

• Primary Outcome: The change of the Japanese Leicester Cough Questionnaire score at 28 days.

Secondary Outcome

The change of the cough severity visual analog scale and the COPD assessment test score at 28 days
All adverse events
Taste-related serious adverse events included ageusia, dysgeusia, hypergeusia, hypogeusia, and taste disorder

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Patients diagnosed with interstitial lung disease
Patients who have been fully informed of the study and given the consent
More than 18 years old patients

Exclude criteria

Patients unable to give the consent
Patients allergic to sulfonamide group
Other patients deemed unsuitable for the study by the principal investigator or the sub-investigator
Patients already taking gefapixant

Related Information

• Primary Sponsor: Abe Mitsuhiro